Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  SIX SWISS EXCHANGE AG  >  Roche Holding Ltd.       CH0012032048

ROCHE HOLDING LTD.
Mes dernières consult.
Most popular
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( CHF)
Sales 2017 53 320 M
EBIT 2017 18 306 M
Net income 2017 11 158 M
Debt 2017 8 848 M
Yield 2017 3,51%
Sales 2018 55 471 M
EBIT 2018 19 426 M
Net income 2018 12 382 M
Debt 2018 4 810 M
Yield 2018 3,69%
P/E ratio 2017 18,28
P/E ratio 2018 16,64
EV / Sales2017 4,13x
EV / Sales2018 3,90x
Capitalization 212 B
More Financials
Company
Roche Holding AG operates as a research healthcare company.It operates through the following segments: Diagnostics and Pharmaceuticals.The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience.The... 
Sector
Pharmaceuticals
Calendar
09/20Presentation
More about the company
Surperformance© ratings of Roche Holding Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING LTD.
07:46a RECIPHARM PUBL : signs long-term manufacturing agreement with major new customer..
09/19 ROCHE : Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan hel..
09/18 ROCHE : Phase III Data Showed That Venclexta Plus Rituxan Helped People With Pre..
09/18 ROCHE : Partitions
09/15 Halozyme signs mammoth drug partnerships
09/14 FOUNDATION MEDICINE : New Breast Cancer Findings from Foundation Medicine Inc. R..
09/14 FOUNDATION MEDICINE : to Present Validation Data for Its Assay Measuring Tumor M..
09/14 ROCHE : 23andMe raises $250m in financing, research points towards its future
09/14 Roche faces prospect of second Rituxan biosimilar in US
09/14 ROCHE : Various medicinal products
More news
Sector news : Pharmaceuticals - NEC
09:01aDJGLAXOSMITHKLINE : Announces Positive Results for Triple-Therapy Inhaler
08:48aDJMakers Of Opioids Are Asked For Data -- WSJ
09/19DJStates Push Ahead With Investigation Into Opioid Painkillers
09/19 BAYER : EU agrees to extend deadline for decision on Bayer, Monsanto deal
09/19 BAYER : dismisses antitrust concerns about digital farming
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 276  CHF
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.220 102
JOHNSON & JOHNSON16.70%363 360
NOVARTIS11.20%223 865
ROCHE HOLDING LTD.4.56%219 130
PFIZER9.45%211 705
MERCK AND COMPANY12.38%179 978